Company Overview of Taiho Pharmaceutical Co., Ltd.
Taiho Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products. Its products include S-1, an oral antimetabolite and a combination of pharmacological compounds; ABI-007(Abraxane, a human serum albumin-bound paclitaxel; TSU-68, an orally administered, small-molecule, multiple receptor tyrosine kinase inhibitor; TAS-102, a novel combination antitumor agent; TAS-118, an antimetabolite solution; and ET-743(trabectedine), a synthetic derivative of a substance extracted from the colonial tunicate ecteinascidia turbinata. The company’s products also comprise TAS-114, an inhibitor of dUTPase, a gatekeeper protein in pyrimidine-metabolism; TAS-115, an ATP-competi...
Founded in 1963
Key Executives for Taiho Pharmaceutical Co., Ltd.
President and Representative Director
Chief Executive Officer of Otsuka Holdings Co., Ltd., President of Otsuka Holdings Co., Ltd. and Representative Director of Otsuka Holdings Co., Ltd.
Head of Production Division - Cmc Center and Director
Compensation as of Fiscal Year 2016.
Taiho Pharmaceutical Co., Ltd. Key Developments
Taiho Pharmaceutical Co., Ltd. Announces Establishment of Taiho Ventures, LLC
May 10 16
Taiho Pharmaceutical Co., Ltd. announced on May 10 that it has established Taiho Ventures, LLC, a strategic corporate venture capital arm of TPC, in California, USA. Taiho Ventures will be investing globally in the start-up companies that discover and develop innovative therapeutic products and/or drug-enabling platform technologies that demonstrate a clear potential to benefit cancer patients. With the support of Taiho's established expertise in the field of oncology product discovery and development, Taiho Ventures will provide financial resources and company outreach to build strategic alliances to help translate novel research and high-potential drug candidates into cornerstone products. Initially, Taiho Ventures will make investments from the pooled amount of $50 million.
Taiho Pharmaceutical Co., Ltd. Wins European Commission Approval for Marketing Authorization for LONSURF
Apr 28 16
Taiho Pharmaceutical Co., Ltd. of Tokyo announced on April 28, 2016, that the European Commission (EC) has granted marketing authorization for LONSURF (R) (trifluridine/tipiracil), formerly known as TAS-102, in the European Union (EU) for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents. LONSURF is an oral anticancer drug, comprising the combination of trifluridine (FTD) and tipiracil (TPI), whose dual mechanism of action is designed to maintain clinical activity. LONSURF was originally developed by Taiho Pharmaceutical, and Servier will co-develop and commercialize LONSURF in EU countries under a license agreement with Taiho Pharmaceutical.
Taiho Pharmaceutical Co., Ltd. Announces Nutritive Drink Tiovita 3000
Apr 11 16
Taiho Pharmaceutical Co., Ltd. announced that it will release the nutritive drink Tiovita 3000 in Hong Kong on April 21, 2016. Tiovita 3000 is a newly developed product based on Tiovita Drink (designated quasidrug), which was originally launched in 1964 in Japan. The new product features a localized taste with a fresh grape flavor and label designed to meet consumer preferences in Hong Kong. It contains several nutritious ingredients, such as taurine, which is known for helping to heal fatigue, and more B vitamins than were in the original Tiovita Drink.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|